TMC-310911
![]() | |
法律規範狀態 | |
---|---|
法律規範 |
|
識別資訊 | |
| |
CAS號 | 1000287-05-7 ![]() |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
化學資訊 | |
化學式 | C38H53N5O7S2 |
摩爾質量 | 755.99 |
3D模型(JSmol) | |
| |
|
TMC-310911(也稱ASC-09)是一種最初被研究用於治療HIV/AIDS的抗病毒藥物。它是一種蛋白酶抑制劑,與達蘆那韋有關。[1][2]儘管TMC-310911在開發後,其最終用途不是用於治療艾滋病,但對於其它病毒性疾病的治療研究仍在進行。它在2020年3月進入了COVID-19治療的臨床試驗階段。[3][4]
參見
參考文獻
- ^ Dierynck I, Van Marck H, Van Ginderen M, Jonckers TH, Nalam MN, Schiffer CA, Raoof A, Kraus G, Picchio G. TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors. Antimicrobial Agents and Chemotherapy. December 2011, 55 (12): 5723–31. PMC 3232804
. PMID 21896904. doi:10.1128/AAC.00748-11.
- ^ Ghosh AK, Brindisi M. Organic carbamates in drug design and medicinal chemistry. Journal of Medicinal Chemistry. April 2015, 58 (7): 2895–940. PMC 4393377
. PMID 25565044. doi:10.1021/jm501371s.
- ^ Catapang JK, Billones JB. On the Generation of Novel Ligands for SARS-CoV-2 Protease and ACE2 Receptor via Constrained Graph Variational Autoencoders. ChemRxiv. March 2020. doi:10.26434/chemrxiv.12011157.v3.
- ^ McGrath J. All the COVID-19 vaccines and treatments currently in clinical trials. Digital Trends. 2 April 2020 [6 April 2020]. (原始內容存檔於2020-04-14).
|